Postoperative Endocrine Therapy for Invasive Breast Cancer

  • Leisha A. Emens
  • Nancy E. Davidson
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

Estrogen plays a key role in mammary carcinogenesis, identifying the pathways that regulate estrogen function as major targets for breast cancer therapy. Expression of the estrogen receptor α (ERα) or the progesterone receptor (PR) is a widely recognized predictor of response to hormonal therapy [1]. Studies of endocrine manipulation conducted in advanced breast cancer have revealed response rates of 80% for ER+/PR+ tumors, 40–45% for ER–/PR+ tumors, 25–30% for ER+/PR– tumors, and less than 10% for ER–/PR– tumors. More recently, data have demonstrated that over-expression of ER or PR in at least 1% of breast tumor cells indicates potential responsiveness to endocrine therapy [2, 3]. In the absence of ER or PR expression, endocrine therapy is not indicated. These observations highlight the importance of an accurate measurement of ER and PR expression in the primary tumor in therapeutic decision-making. Currently, quality-controlled quantitative immunohistochemistry is the method of choice [4, 5].


Breast Cancer Overall Survival Premenopausal Woman Aromatase Inhibitor Luteinizing Hormone Release Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46(12 Suppl):2884–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Harvey J, Clark G, Osborne C, Allred D. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.PubMedGoogle Scholar
  3. 3.
    Mohsin S, Wiess H, Gutierrez M, et al. Neoadjuvant Trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005;23:2460–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Goldhirsch A, Wood W, Gelber R, et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Zafrani B, Aubriot H, Mouret E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: Comparison with biochemical determination in a prospective study of 793 cases. Histopathol. 2000;37:536–45.CrossRefGoogle Scholar
  6. 6.
    Clarke M. Ovarian ablation in breast cancer, 1896–1998: Milestones along hierarchy of evidence from case report to Cochrane review. BM J. 1998;317:1246–8.CrossRefGoogle Scholar
  7. 7.
    Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–42.PubMedCrossRefGoogle Scholar
  8. 8.
    Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol. 2000;18(17):3172–86.PubMedGoogle Scholar
  9. 9.
    Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A. 1992;89(9):4037–41.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  11. 11.
    Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Sorlie T, Perou C, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Dowsett M, Harper-Wynne C, Beoddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001;61:8452–8.PubMedGoogle Scholar
  15. 15.
    Moy B, Goss P. Estrogen receptor pathways: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006;15:4790–3.CrossRefGoogle Scholar
  16. 16.
    Choi J, Nowell S, Blanco J, Ambrosone C. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 2006;7:613–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Wiebe V, Osborne C, Fuqua S, DeGregorio M. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol. 1993;14:173–88.PubMedCrossRefGoogle Scholar
  18. 18.
    Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: Update 2006. CA Cancer J for Clinicians. 2006;56:168–83.CrossRefGoogle Scholar
  19. 19.
    Pujol P, Daures J, Thezenas S, et al. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer. 1998;83:698–705.PubMedCrossRefGoogle Scholar
  20. 20.
    Goldhirsch A, Glick J, Gelber R, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol. 2001;19(18):3817–27.PubMedGoogle Scholar
  21. 21.
    Prowell T, Davidson N. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist. 2004;9:507–17.PubMedCrossRefGoogle Scholar
  22. 22.
    Goldhirsch A, Glick J, Gelber R, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Annals Oncol. 2005;16:1569–83.CrossRefGoogle Scholar
  23. 23.
    Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-related, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen-receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Early Breast Cancer Clinical Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: Overview of the randomized trials. Lancet. 1998;351:1451–67.CrossRefGoogle Scholar
  26. 26.
    Nolvadex Adjuvant Trial Organization (NATO). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer. 1988;57:608–11.CrossRefGoogle Scholar
  27. 27.
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Stewart H. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst. 1992;11:117–20.Google Scholar
  30. 30.
    Stewart H, Forrest A, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet. 1996;348:708–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Stewart H, Prescott R, Forrest A. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst. 2001;93:456–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Boccardo F, Amoroso D, Rubagotti A, et al. Endocrine therapy of breast cancer: The experience of the Italian cooperative group for chemohormonal therapy of early breast cancer. Annals New York Acad Sci. 1993;698:318–29.CrossRefGoogle Scholar
  33. 33.
    Kaufmann M, Jonat W, Abel U, et al. Adjuvant randomized trials of doxorubicin/cyclo-phosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol. 1993;11:454–60.PubMedGoogle Scholar
  34. 34.
    Tormey DC, Gray R, Abeloff MD, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol. 1992;10:1848–56.PubMedGoogle Scholar
  35. 35.
    Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006;24:1332–41.PubMedCrossRefGoogle Scholar
  36. 36.
    Beatson G. On the treatment of inoperable cases of carcinoma of the mamm: Suggestions for new method of treatment. Lancet. 1896;2:104–7.CrossRefGoogle Scholar
  37. 37.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet. 1996;348:1189–96.CrossRefGoogle Scholar
  38. 38.
    Scottish Cancer Trials Breast Group and ICRF, Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet. 1993;341:1293–8.Google Scholar
  39. 39.
    Ejlertsen B, Mouridsen H, Jensen M, et al. Similar efficacy for ovarian ablation compared with cylcophosphamide, methotrexate, and fluorouracil: From a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol. 2006;24:4956–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Schmid P, Untch M, Wallwiener D, et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res. 2002;22:2325–32.PubMedGoogle Scholar
  41. 41.
    Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. J Clin Oncol. 2002;20:4628–35.PubMedCrossRefGoogle Scholar
  42. 42.
    Petrek J, Naughton M, Case L, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol. 2006;24:1045–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Goldhirsch A, Gelber R, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001;30:44–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Davidson N, O'Neill A, Vukov A, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT0101 (E5188). J Clin Oncol. 2005;23:5973–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer. 2006;42:895–904.PubMedCrossRefGoogle Scholar
  46. 46.
    International Breast Cancer Research Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93. Breast. 2001;10:130–8.Google Scholar
  47. 47.
    Castiglione-Gertsch M, O'Neill A, Price K, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst. 2003;95:1833–46.PubMedCrossRefGoogle Scholar
  48. 48.
    Arriagada R, Le M, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjvuant chemotherapy. Annals Oncol. 2005;16:389–96.CrossRefGoogle Scholar
  49. 49.
    Robert N, Wang M, Wood W. Phase III comparison of tamoxifen with ovarian ablation in premenopausal women with axillary node-negative, receptor-positive breast cancer <3 cm. Proc Am Soc Clin Oncol. 2003;22:16a.Google Scholar
  50. 50.
    Love R, Duc N, Allred D, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20:2559–66.PubMedCrossRefGoogle Scholar
  51. 51.
    Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000;18:2718–27.PubMedGoogle Scholar
  52. 52.
    Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Annals Oncol. 2006;17:1221–7.CrossRefGoogle Scholar
  53. 53.
    Roche H, Mihura J, de Lafontan B, et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node- and receptor-positive breast cancer patients: A randomized trial with a 7 years median follow up. Proc Am Soc Clin Oncol. 1996;15:117.Google Scholar
  54. 54.
    The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: Results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J Natl Cancer Inst. 2007;99:516–25.PubMedCrossRefGoogle Scholar
  55. 55.
    Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20:4621–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet. 2007;369:1711–23.CrossRefGoogle Scholar
  57. 57.
    Paik S. Molecular profiling of breast cancer. Curr Opin Obst Gynecol. 2006;18:59–62.CrossRefGoogle Scholar
  58. 58.
    Kennecke H, Olivotto I, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Annals Oncol. 2007;18:45–51.CrossRefGoogle Scholar
  59. 59.
    Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr. 2001;30:56–61.PubMedCrossRefGoogle Scholar
  60. 60.
    Baum M, Budzar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359:2131–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–2.PubMedCrossRefGoogle Scholar
  62. 62.
    Thurlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG) 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.PubMedCrossRefGoogle Scholar
  63. 63.
    Coates A, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol. 2007;25:486–92.PubMedCrossRefGoogle Scholar
  64. 64.
    Ryan P, Goss P. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. The Oncologist. 2006;11: 718–31.PubMedCrossRefGoogle Scholar
  65. 65.
    Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23:5138–47.CrossRefGoogle Scholar
  66. 66.
    Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–62.PubMedCrossRefGoogle Scholar
  67. 67.
    Kaufmann M, Jonat W, Hilfrich H, et al. Survival benefit of switching to anastrozole after 2 years of treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study (abstract 547). J Clin Oncol. 2006;24(18S):14s.Google Scholar
  68. 68.
    Coombes R, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.PubMedCrossRefGoogle Scholar
  69. 69.
    Coombes R, Kilburn L, Snowdon C, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet. 2007;369:559–70.PubMedCrossRefGoogle Scholar
  70. 70.
    Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.PubMedCrossRefGoogle Scholar
  71. 71.
    Goss P, Ingle J, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71.PubMedCrossRefGoogle Scholar
  72. 72.
    Robert N, Goss P, Ingle J, et al.. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding (abstract 550). Proc Am Soc Clin Oncol. 2006;24(18s):5s.Google Scholar
  73. 73.
    Goss P, Ingle J, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007;25:2006–11.PubMedCrossRefGoogle Scholar
  74. 74.
    Ingle J, Tu D, Pater J, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006;99:295–300.PubMedCrossRefGoogle Scholar
  75. 75.
    Jakesz R, Samonigg R, Greil M, et al. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc Am Soc Clin Oncol. 2005;23(16s):10s.Google Scholar
  76. 76.
    Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol. 2006;7:991–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bone mineral density and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Mineral Res. 2006;21:1215–23.CrossRefGoogle Scholar
  78. 78.
    Coleman R, Banks L, Girgis S, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol. 2007;8:119–27.PubMedCrossRefGoogle Scholar
  79. 79.
    Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35.PubMedCrossRefGoogle Scholar
  80. 80.
    National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr. 2001;30:5–15.Google Scholar
  81. 81.
    Winer E, Hudis C, Burstein H, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol. 2005;23:619–29.PubMedCrossRefGoogle Scholar
  82. 82.
    Smith I, Dowsett M, Yap Y, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol. 2006;24:2444–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of OncologyThe Johns Hopkins UniversityBaltimoreUSA
  2. 2.University of Pittsburgh Cancer Institute, University of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations